Brainstorm Cell Therapeutics (BCLI)
Brainstorm Cell Therapeutics on one page: short interest, daily short volume, fails to deliver, earnings dates and insider trades. Listed on OTC, classified by the SEC as biological products, (no diagnostic substances).
34K
Short interest
settlement 2026-10-15
1.5
Days to cover
unchanged vs prior
71.6%
Short share of volume
2025-07-17
4,962
Fails to deliver
settlement 2026-08-19
Fri 13 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-10-15.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in BCLI is 34,232 shares, down 8,212 shares over the last month. Over the last 48 readings it ranged from 34,232 shares (15 October 2026) to 604,460 shares (30 June 2025). The latest reading sits at the bottom of that range. At the reported average volume of 23K shares a day that is 1.5 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/bcli" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 34,232 | -6.1% | 23,350 | 1.47 |
| 2026-09-30 | 36,461 | -14.1% | 25,299 | 1.44 |
| 2026-09-15 | 42,444 | -13.5% | 31,374 | 1.35 |
| 2026-08-31 | 49,072 | +2.8% | 109,033 | 1.00 |
| 2026-08-14 | 47,737 | +1.5% | 50,105 | 1.00 |
| 2026-07-31 | 47,029 | +3.0% | 18,993 | 2.48 |
| 2026-07-15 | 45,668 | -22.3% | 105,938 | 1.00 |
| 2026-06-30 | 58,736 | -0.7% | 22,462 | 2.61 |
| 2026-06-15 | 59,174 | +9.0% | 30,791 | 1.92 |
| 2026-05-29 | 54,300 | +1.7% | 22,784 | 2.38 |
| 2026-05-15 | 53,390 | +0.1% | 13,168 | 4.05 |
| 2026-04-30 | 53,310 | -19.1% | 22,451 | 2.37 |
| 2026-04-15 | 65,893 | -30.4% | 20,785 | 3.17 |
| 2026-03-31 | 94,649 | -32.8% | 36,930 | 2.56 |
| 2026-03-13 | 140,773 | -48.3% | 51,433 | 2.74 |
| 2026-02-27 | 272,453 | +1.8% | 51,723 | 5.27 |
| 2026-02-13 | 267,707 | -0.3% | 44,843 | 5.97 |
| 2026-01-30 | 268,529 | +0.2% | 31,991 | 8.39 |
| 2026-01-15 | 268,113 | -0.9% | 33,916 | 7.91 |
| 2025-12-31 | 270,535 | -0.1% | 75,941 | 3.56 |
| 2025-12-15 | 270,666 | -0.8% | 44,546 | 6.08 |
| 2025-11-28 | 272,945 | -2.6% | 38,667 | 7.06 |
| 2025-11-14 | 280,225 | +1.2% | 27,927 | 10.03 |
| 2025-10-31 | 276,965 | -1.1% | 31,300 | 8.85 |
| 2025-10-15 | 280,130 | -6.7% | 44,471 | 6.30 |
| 2025-09-30 | 300,362 | -8.2% | 45,421 | 6.61 |
| 2025-09-15 | 327,152 | -4.5% | 39,898 | 8.20 |
| 2025-08-29 | 342,635 | -1.6% | 61,190 | 5.60 |
| 2025-08-15 | 348,234 | -19.3% | 156,516 | 2.22 |
| 2025-07-31 | 431,321 | -23.9% | 614,484 | 1.00 |
| 2025-07-15 | 566,390 | -6.3% | 422,865 | 1.34 |
| 2025-06-30 | 604,460 | +30.5% | 449,766 | 1.34 |
| 2025-06-13 | 463,315 | -13.7% | 430,860 | 1.08 |
| 2025-05-30 | 536,937 | +156.3% | 6,614,599 | 1.00 |
| 2025-05-15 | 209,504 | -28.1% | 117,744 | 1.78 |
| 2025-04-30 | 291,418 | -15.9% | 157,119 | 1.85 |
| 2025-04-15 | 346,646 | +152.6% | 610,656 | 1.00 |
| 2025-03-31 | 137,216 | +11.8% | 46,715 | 2.94 |
| 2025-03-14 | 122,765 | +14.5% | 16,867 | 7.28 |
| 2025-02-28 | 107,230 | -3.3% | 37,546 | 2.86 |
| 2025-02-14 | 110,846 | +21.3% | 32,897 | 3.37 |
| 2025-01-31 | 91,385 | -47.2% | 63,905 | 1.43 |
| 2025-01-15 | 172,989 | +85.5% | 57,202 | 3.02 |
| 2024-12-31 | 93,267 | -38.8% | 159,130 | 1.00 |
| 2024-12-13 | 152,370 | +2.8% | 85,033 | 1.79 |
| 2024-11-29 | 148,229 | -14.7% | 99,445 | 1.49 |
| 2024-11-15 | 173,850 | +58.3% | 162,693 | 1.07 |
| 2024-10-31 | 109,802 | -33.8% | 87,664 | 1.25 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 17 July 2025, the short share of BCLI volume is 71.6%, up 11.7 points over the last five sessions. Over the last 30 readings it ranged from 29.4% (9 June 2025) to 72.0% (17 June 2025). The latest reading sits at the top of that range. The latest reading is 17.2 points above the 30-session average of 54.4%, on 647K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2025-07-17 | 463K | 647K | 71.6% | 64,850 |
| 2025-07-16 | 78K | 184K | 42.5% | 5,644 |
| 2025-07-15 | 57K | 107K | 53.0% | 374 |
| 2025-07-14 | 49K | 121K | 40.7% | 0 |
| 2025-07-11 | 97K | 151K | 64.1% | 4,869 |
| 2025-07-10 | 60K | 100K | 59.9% | 91 |
| 2025-07-09 | 125K | 268K | 46.7% | 7,939 |
| 2025-07-08 | 617K | 1.0M | 59.2% | 5,363 |
| 2025-07-07 | 68K | 112K | 60.8% | 3,227 |
| 2025-07-03 | 38K | 65K | 58.0% | 2,105 |
| 2025-07-02 | 100K | 177K | 56.3% | 500 |
| 2025-07-01 | 76K | 139K | 54.5% | 138 |
| 2025-06-30 | 93K | 155K | 60.1% | 0 |
| 2025-06-27 | 182K | 274K | 66.3% | 0 |
| 2025-06-26 | 103K | 226K | 45.7% | 590 |
| 2025-06-25 | 76K | 126K | 59.8% | 250 |
| 2025-06-24 | 145K | 269K | 53.8% | 913 |
| 2025-06-23 | 167K | 282K | 59.3% | 326 |
| 2025-06-20 | 385K | 657K | 58.6% | 16,748 |
| 2025-06-18 | 91K | 170K | 53.3% | 0 |
| 2025-06-17 | 152K | 211K | 72.0% | 0 |
| 2025-06-16 | 243K | 440K | 55.3% | 293 |
| 2025-06-13 | 73K | 137K | 53.3% | 201 |
| 2025-06-12 | 39K | 101K | 39.0% | 0 |
| 2025-06-11 | 148K | 330K | 44.9% | 9,363 |
| 2025-06-10 | 397K | 741K | 53.6% | 1,201 |
| 2025-06-09 | 31K | 105K | 29.4% | 0 |
| 2025-06-06 | 151K | 352K | 42.9% | 0 |
| 2025-06-05 | 67K | 115K | 58.1% | 1,228 |
| 2025-06-04 | 150K | 252K | 59.6% | 1,445 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 19 August 2026, the fails-to-deliver balance in BCLI is 4,962 shares, up 4,862 shares over the last settlement date. Over the last 30 readings it ranged from 3 shares (4 August 2025) to 9,369 shares (11 December 2025).
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-19 | 4,962 | $1.41 | $7K |
| 2026-06-10 | 100 | $0.76 | $76 |
| 2026-03-05 | 67 | $0.65 | $44 |
| 2026-02-24 | 311 | $0.62 | $193 |
| 2026-02-06 | 88 | $0.58 | $51 |
| 2026-01-30 | 62 | $0.62 | $38 |
| 2026-01-29 | 62 | $0.62 | $38 |
| 2026-01-07 | 100 | $0.59 | $59 |
| 2026-01-06 | 300 | $0.57 | $171 |
| 2025-12-17 | 1,300 | $0.58 | $754 |
| 2025-12-16 | 1,300 | $0.55 | $715 |
| 2025-12-11 | 9,369 | $0.56 | $5K |
| 2025-12-08 | 627 | $0.60 | $376 |
| 2025-11-26 | 15 | $0.62 | $9 |
| 2025-11-25 | 15 | $0.64 | $10 |
| 2025-11-24 | 15 | $0.64 | $10 |
| 2025-11-21 | 15 | $0.64 | $10 |
| 2025-10-29 | 49 | $0.69 | $34 |
| 2025-10-14 | 1,000 | $0.66 | $660 |
| 2025-10-09 | 267 | $0.73 | $195 |
| 2025-09-11 | 286 | $0.74 | $212 |
| 2025-09-10 | 360 | $0.78 | $281 |
| 2025-09-09 | 128 | $0.70 | $90 |
| 2025-08-29 | 201 | $0.73 | $147 |
| 2025-08-22 | 5,055 | $0.63 | $3K |
| 2025-08-18 | 258 | $0.63 | $163 |
| 2025-08-04 | 3 | $0.67 | $2 |
| 2025-08-01 | 6 | $0.71 | $4 |
| 2025-07-30 | 2,882 | $0.74 | $2K |
| 2025-07-24 | 4,887 | $0.69 | $3K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for BCLI in the last 90 days. The most recent filings are listed below. Latest filing: FRENKEL JACOB A (Director) on 2026-07-24.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-07-24 | FRENKEL JACOB A | Director | Grant | 100K | $0.00 | $0 | 344K |
| 2026-02-26 | Lebovits Chaim | President & CEO | Grant | 1.8M | $0.00 | $0 | 2.0M |
| 2026-02-26 | Yablonka Uri | EVP & Chief Business Officer | Grant | 150K | $0.00 | $0 | 218K |
| 2026-02-26 | Patlis Alla | See Remarks | Grant | 100K | $0.00 | $0 | 144K |
| 2026-02-26 | FRENKEL JACOB A | Director | Grant | 200K | $0.00 | $0 | 244K |
| 2026-02-26 | ARBEL IRIT | Director | Grant | 120K | $0.00 | $0 | 161K |
| 2025-01-01 | ARBEL IRIT | Director | Grant | 31K | $0.00 | $0 | 41K |
| 2025-01-01 | Bairu Menghisteab | Director | Grant | 24K | $0.00 | $0 | 24K |
| 2025-01-01 | HARTOUNIAN HARTOUN | EVP, Chief Operating Officer | Grant | 50K | $0.00 | $0 | 52K |
| 2025-01-01 | Lindborg Stacy | Director | Grant | 20K | $0.00 | $0 | 48K |
| 2025-01-01 | Naor Nir | Director | Grant | 31K | $0.00 | $0 | 31K |
| 2025-01-01 | Patlis Alla | See Remarks | Grant | 40K | $0.00 | $0 | 44K |
| 2025-01-01 | Yablonka Uri | EVP & Chief Business Officer | Grant | 20K | $0.00 | $0 | 68K |
| 2025-01-01 | Yablonka Uri | EVP & Chief Business Officer | Grant | 40K | $0.00 | $0 | 48K |
| 2025-01-01 | Polverino Anthony J. | Director | Grant | 24K | $0.00 | $0 | 26K |
| 2025-01-01 | FRENKEL JACOB A | Director | Grant | 40K | $0.00 | $0 | 44K |
| 2025-01-01 | Lebovits Chaim | President & CEO | Grant | 120K | $0.00 | $0 | 201K |
| 2025-01-01 | Dagher Ibrahim B. | Chief Medical Officer | Grant | 50K | $0.00 | $0 | 67K |
| 2024-10-01 | Lebovits Chaim | President & CEO | Buy | 2K | $3.43 | $6K | 81K |
| 2024-09-30 | Lebovits Chaim | President & CEO | Buy | 22K | $0.23 | $5K | 1.2M |
| 2024-07-19 | Dagher Ibrahim B. | Chief Medical Officer | Sell | 63K | $0.35 | $22K | 0 |
| 2024-06-24 | HARTOUNIAN HARTOUN | EVP, Chief Operating Officer | Grant | 30K | $0.00 | $0 | 30K |
| 2024-05-28 | Lebovits Chaim | President & CEO | Buy | 15K | $0.52 | $8K | 1.2M |
| 2024-05-28 | Lebovits Chaim | President & CEO | Grant | 15K | $0.52 | $8K | 1.2M |
| 2024-05-22 | Lebovits Chaim | President & CEO | Buy | 25K | $0.64 | $16K | 1.1M |
| 2024-05-22 | Lebovits Chaim | President & CEO | Grant | 25K | $0.64 | $16K | 1.1M |
| 2024-05-21 | Lebovits Chaim | President & CEO | Buy | 25K | $0.58 | $15K | 1.1M |
| 2024-05-21 | Lebovits Chaim | President & CEO | Grant | 25K | $0.58 | $15K | 1.1M |
| 2024-05-13 | Lebovits Chaim | President & CEO | Buy | 10K | $0.49 | $5K | 1.1M |
| 2024-05-13 | Lebovits Chaim | President & CEO | Grant | 10K | $0.49 | $5K | 1.1M |
| 2024-05-11 | Lebovits Chaim | President & CEO | Buy | 10K | $0.47 | $5K | 1.1M |
| 2024-05-11 | Lebovits Chaim | President & CEO | Grant | 10K | $0.47 | $5K | 1.1M |
| 2024-05-10 | Lebovits Chaim | President & CEO | Buy | 20K | $0.47 | $9K | 1.1M |
| 2024-05-10 | Lebovits Chaim | President & CEO | Grant | 20K | $0.47 | $9K | 1.1M |
| 2024-05-07 | Lebovits Chaim | President & CEO | Buy | 66K | $0.37 | $25K | 1.1M |
| 2024-05-07 | Lebovits Chaim | President & CEO | Grant | 66K | $0.37 | $25K | 1.1M |
| 2024-05-06 | Lebovits Chaim | President & CEO | Buy | 135K | $0.38 | $51K | 994K |
| 2024-05-06 | Lebovits Chaim | President & CEO | Grant | 135K | $0.38 | $51K | 994K |
| 2024-04-19 | Lebovits Chaim | President & CEO | Buy | 15K | $0.52 | $8K | 859K |
| 2024-04-19 | Lebovits Chaim | President & CEO | Grant | 15K | $0.52 | $8K | 859K |
| 2024-04-18 | Lebovits Chaim | President & CEO | Buy | 115K | $0.53 | $61K | 844K |
| 2024-04-18 | Lebovits Chaim | President & CEO | Grant | 115K | $0.53 | $61K | 844K |
| 2024-04-17 | Lebovits Chaim | President & CEO | Buy | 130K | $0.55 | $72K | 728K |
| 2024-04-17 | Lebovits Chaim | President & CEO | Grant | 130K | $0.55 | $72K | 728K |
| 2024-03-11 | Lebovits Chaim | President & CEO | Grant | 305K | $0.00 | $0 | 598K |
| 2024-03-11 | Patlis Alla | See Remarks | Grant | 65K | $0.00 | $0 | 65K |
| 2024-03-11 | Yablonka Uri | EVP & Chief Business Officer | Grant | 109K | $0.00 | $0 | 127K |
| 2024-03-11 | Lindborg Stacy | Co-Chief Executive Officer | Grant | 242K | $0.00 | $0 | 423K |
| 2023-09-01 | Lindborg Stacy | Co-Chief Executive Officer | Buy | 12K | $1.77 | $20K | 182K |
| 2023-08-02 | Lebovits Chaim | President & CEO | Grant | 31K | $0.00 | $0 | 293K |
| 2023-08-02 | Lindborg Stacy | Co-Chief Executive Officer | Grant | 35K | $0.00 | $0 | 170K |
| 2023-06-19 | Naor Nir | Director | Grant | 12K | $0.00 | $0 | 12K |
| 2023-05-01 | Taylor Kirk | Chief Medical Officer | Grant | 35K | $0.00 | $0 | 35K |
| 2023-04-20 | Lindborg Stacy | Co-Chief Executive Officer | Grant | 75K | $0.00 | $0 | 135K |
| 2023-04-20 | Lebovits Chaim | President & Co-CEO | Grant | 75K | $0.00 | $0 | 262K |
| 2022-12-07 | Lindborg Stacy | Co-Chief Executive Officer | Grant | 35K | $0.00 | $0 | 60K |
| 2022-09-18 | Lebovits Chaim | Chief Executive Officer | Grant | 31K | $0.00 | $0 | 187K |
| 2022-03-06 | Kern Ralph Dr. | COO and Chief Medical Officer | Grant | 36K | $0.00 | $0 | 223K |
| 2022-02-01 | Polverino Anthony J. | Director | Grant | 4K | $0.00 | $0 | 26K |
| 2021-12-15 | Almenoff June Sherie | Director | Grant | 2K | $0.00 | $0 | 6K |
| 2021-12-15 | Polverino Anthony J. | Director | Grant | 2K | $0.00 | $0 | 22K |
| 2021-12-15 | TAUB MALCOLM S | Director | Grant | 12K | $0.00 | $0 | 77K |
| 2021-12-10 | Almenoff June Sherie | Director | Grant | 2K | $0.00 | $0 | 4K |
| 2021-12-10 | Abbhi Sankesh | Director | Grant | 7K | $0.00 | $0 | 11K |
| 2021-12-10 | Polverino Anthony J. | Director | Grant | 2K | $0.00 | $0 | 18K |
| 2021-12-10 | Polverino Anthony J. | Director | Grant | 2K | $0.00 | $0 | 20K |
| 2021-12-10 | TAUB MALCOLM S | Director | Grant | 12K | $0.00 | $0 | 65K |
| 2021-12-10 | Lebovits Chaim | Chief Executive Officer | Grant | 31K | $0.00 | $0 | 156K |
| 2021-12-10 | Kern Ralph Dr. | COO and Chief Medical Officer | Grant | 36K | $0.00 | $0 | 187K |
| 2020-12-30 | Shah Preetam | EVP, CFO and Treasurer | Tax withholding | 25K | $4.64 | $116K | 12K |
| 2020-09-08 | Waclawski Anthony | See Remarks | Grant | 35K | $0.00 | $0 | 35K |
| 2020-07-26 | Lebovits Chaim | Chief Executive Officer | Grant | 31K | $0.00 | $0 | 125K |
| 2020-07-16 | ACC International Holdings Ltd. | Other | Sell | 8K | $13.47 | $105K | 67K |
| 2020-07-16 | Setboun David | EVP and COO | Buy | 5K | $12.95 | $65K | 55K |
| 2020-07-15 | ACC International Holdings Ltd. | Other | Sell | 18K | $13.12 | $242K | 75K |
| 2020-07-15 | Abbhi Sankesh | Director | Buy | 47K | $12.99 | $608K | 2.2M |
| 2020-07-13 | ACC International Holdings Ltd. | Other | Sell | 40K | $13.52 | $541K | 93K |
| 2020-07-10 | ACC International Holdings Ltd. | Other | Sell | 2K | $13.35 | $27K | 133K |
| 2020-07-09 | ACC International Holdings Ltd. | Other | Sell | 4K | $13.13 | $46K | 135K |
| 2020-06-23 | Yablonka Uri | EVP & Chief Business Officer | Grant | 10K | $0.00 | $0 | 18K |
| 2020-06-01 | Lindborg Stacy | EVP, Head Global Clin Research | Grant | 25K | $0.00 | $0 | 25K |
| 2020-04-07 | Setboun David | EVP and COO | Grant | 50K | $0.00 | $0 | 50K |
| 2020-04-06 | Abbhi Sankesh | Director | Grant | 5K | $0.00 | $0 | 5K |
| 2020-03-06 | Kern Ralph Dr. | COO and Chief Medical Officer | Grant | 36K | $0.00 | $0 | 152K |
| 2020-02-01 | Polverino Anthony J. | Director | Grant | 3K | $0.00 | $0 | 16K |
| 2019-12-12 | Polverino Anthony J. | Director | Grant | 2K | $0.00 | $0 | 13K |
| 2019-12-12 | TAUB MALCOLM S | Director | Grant | 12K | $0.00 | $0 | 53K |
| 2019-12-12 | Almenoff June Sherie | Director | Grant | 2K | $0.00 | $0 | 2K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
What this page is
Brainstorm Cell Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Brainstorm Cell Therapeutics (BCLI), SEC CIK 1137883, listed on OTC, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2025-07-17.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-08-19.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-14.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-07-24.JSON and CSV
- Company record
- EDGAR filing index for CIK 1137883Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of BCLI is sold short?
34,232 shares were held short at the 2026-10-15 settlement, 1.5 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is BCLI's daily short volume?
On 2025-07-17, 463,190 of the 646,813 BCLI shares reported to FINRA were sold short, 71.6% of the day's reported volume. Short volume is a flow for one day, not a position.
Does BCLI have fails to deliver?
The SEC's latest file shows 4,962 BCLI shares failed to deliver at settlement 2026-08-19. Fails are reported per settlement date and published twice a month with a lag.
Are BCLI insiders buying or selling?
No open-market insider trades were reported for BCLI in the last 90 days. The most recent filings are listed below. Latest filing: FRENKEL JACOB A (Director) on 2026-07-24.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.